AI drug validation startup Polyphron raises $20M seed from Gradient, Quiet, Compound
darian314 · x · 2026-09-17
Polyphron announced a $20M seed round backed by Gradient, Quiet Capital and Compound, as reported by Axios. Founded by Matthew Osman, the startup builds human tissue models and generation technology to validate AI-created drugs, aiming to get new medicines to market faster and more safely.
More from Venture
- Enterprise AI's real game: getting companies to spend far more, not less — inductionheads · 2026-11-02
- OpenAI has raised less than half of its $30B target in latest funding round, WSJ reports — pstAsiatech · 2026-11-02
- What 150k-follower Bilibili gaming creators charge: 8,500 yuan per video — ezshine · 2026-11-02
- Microsoft issues $25B bonds in $92.28B revenue week as OpenAI trims round by $10B — YvesMulkers · 2026-11-02
- Amazon's $215B capex exceeds $168B operating cash flow, FCF turns -$42B — thealexbanks · 2026-11-02
- A four-dimension framework for building GEO prompt libraries, backed by B2B survey data — yangyi · 2026-11-02